Company Monitoring Page for Novartis

latest headlines for company on cafepharma

ASH: Novartis stays the course with cell therapy bet as competitors line up 'off-the-shelf' options
Fierce Biotech
Tue, 12/13/22 - 10:36 am
Tags:
Novartis, ASH 2022, CAR-T, T-Charge
ASH: Novartis says rare disease med 'stands on its own,' diving deeper into head-to-head win against AstraZeneca
Fierce Biotech
Tue, 12/13/22 - 10:28 am
Tags:
ASH 2022, Novartis, iptacopan, AstraZeneca
Clovis files for bankruptcy, will keep operating and plans to sell pipeline asset to Novartis
Endpoints
Mon, 12/12/22 - 10:14 am
Tags:
Clovis Oncology, bankruptcy, Novartis
Novartis' iptacopan meets PhIII test in fight against rare blood disease
Endpoints
Thu, 12/8/22 - 10:37 am
Tags:
Novartis, clinical trials, paroxysmal nocturnal hemoglobinuria, iptacopan
Novartis’ Kisqali Hits Mark in Mid-Stage Breast Cancer Trial
BioSpace
Wed, 12/7/22 - 11:39 pm
Tags:
Novartis, Kisqali, breast cancer, clinical trials
In Face of Multiple Patent Cliffs, Novartis' Prostate Cancer Drug Shows Promise
BioSpace
Mon, 12/5/22 - 10:58 am
Tags:
Novartis, prostate cancer, Pluvicto, clinical trials, patents, patent cliff
Go or no go? Mirati heads to the FDA
EP Vantage
Wed, 11/30/22 - 10:34 am
Tags:
FDA, Mirati Therapeutics, Gilead Sciences, Coherus Biosciences, Roche, Biogen, TG Therapeutics, Ipsen, Novartis, BeiGene, Cytokinetics
Racing rising resistance, Novartis marches malaria therapy into phase 3
Fierce Biotech
Wed, 11/23/22 - 07:55 am
Tags:
Novartis, malaria, Medicines for Malaria, clinical trials, ganaplacide
Novartis weighs sale of ophthalmology, respiratory units
Yahoo/Reuters
Wed, 11/16/22 - 12:05 pm
Tags:
Novartis, Respiratory, ophthalmology
Novartis halts phase 1 cancer trial of CD73 antagonist over efficacy, but combo studies continue
Fierce Biotech
Wed, 11/16/22 - 10:40 am
Tags:
Novartis, clinical trials, NZV930
Lantheus has three shots on goal to challenge Novartis
EP Vantage
Wed, 11/16/22 - 10:19 am
Tags:
Lantheus Medical, Novartis, Point Biopharma, Pluvicto, Luthathera
In transition and tumult, Seagen names former Novartis oncology chief Epstein as new CEO
Fierce Pharma
Thu, 11/10/22 - 10:47 am
Tags:
Seagen, Pharma CEOs, Novartis, Clay Siegall, David Epstein
Novartis cuts 275 jobs at Illinois site to consolidate Zolgensma manufacturing in North Carolina
Endpoints
Wed, 11/9/22 - 11:13 pm
Tags:
Novartis, layoffs, gene therapy, Zolgensma, drug manufacturing
ASH preview – waiting for Editas
EP Vantage
Wed, 11/9/22 - 10:40 am
Tags:
ASH 2022, sickle cell disease, Bluebird Bio, Sangamo BioSciences, Novartis, Editas Medicine, gene therapy, Vertex Pharmaceuticals, Sanofi
If at first... pharma’s most drawn-out development timelines revealed
EP Vantage
Thu, 11/3/22 - 10:54 am
Tags:
Kyowa Kirin, Takeda, Eiger BioPharmaceuticals, AstraZeneca, Teva Pharmaceutical, Bavarian Nordic, Halozyme, Novartis, MannKind, drug development
What is Novartis without Sandoz? Vas Narasimhan is 'patient' as new company takes form
Endpoints
Tue, 10/25/22 - 11:13 pm
Tags:
Novartis, Pharma CEOs, Vas Narasimhan
Novartis sales of Zolgensma gene therapy slow as market shifts
BioPharma Dive
Tue, 10/25/22 - 11:02 pm
Tags:
Novartis, gene therapy, spinal muscular atrophy, SMA, Zolgensma
Novartis drops presbyopia drug acquired with Encore Vision
Pharmaphorum
Tue, 10/25/22 - 10:32 am
Tags:
Novartis, presbyopia, UNR844, Encore VIsion
Novartis, eyeing $3B market, beats AstraZeneca blood disorder blockbusters in phase 3
Fierce Biotech
Mon, 10/24/22 - 11:17 pm
Tags:
Novartis, iptacopan, clinical trials, Soliris, AstraZeneca, Ultomiris
Novartis’ oral drug iptacopan tops injectables in head-to-head PNH trial
Pharmaphorum
Mon, 10/24/22 - 10:47 am
Tags:
Novartis, iptacopan, clinical trials, PNH

Pages

last 30 twitter posts

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.